Colorectal Cancer Therapeutics Market Size To Increase USD 18.25 Billion By 2032

The global colorectal cancer therapeutics market size was estimated at US$ 12.23  billion in 2023 and is projected to reach US$ 18.25 billion by 2032, indicating a CAGR of 4.55% from 2023 to 2032.

Key Takeaways

  • North America contributed the highest market share of 38% in 2022.
  • Asia-Pacific is estimated to expand the fastest CAGR between 2023 and 2032.
  • By therapy, the immunotherapy segment has held the largest market share of 49% in 2022.
  • By therapy, the targeted therapy segment is anticipated to grow at a remarkable CAGR of 6.9% between 2023 and 2032.
  • By cancer type, the colorectal adenocarcinoma segment has held the largest market share of 47% in 2022.
  • By distribution channel, the hospital pharmacies segment has held the largest market share of 45% in 2022.
  • By distribution channel, the retail pharmacies segment is anticipated to grow at a remarkable CAGR of 7.4% between 2023 and 2032.

The Colorectal Cancer Therapeutics Market is a dynamic sector within the broader pharmaceutical industry, dedicated to addressing the challenges posed by colorectal cancer. Colorectal cancer, affecting the colon or rectum, represents a significant global health concern. The market encompasses a range of therapeutic approaches, including surgery, chemotherapy, targeted therapies, and immunotherapy, all aimed at combating this form of cancer.

Colorectal Cancer Therapeutics Market Size 2023 To 2032

Region Snapshot

The market for colorectal cancer therapeutics exhibits a global presence, with a considerable focus on developed regions such as North America and Europe. However, emerging economies in Asia-Pacific and Latin America also play a crucial role, as the prevalence of colorectal cancer rises in these regions. The diverse regional landscape demands tailored strategies to address specific healthcare infrastructures, regulatory environments, and patient demographics.

Get a Sample:

Growth Factors:

Factors driving the growth of the Colorectal Cancer Therapeutics Market include an aging population, increased awareness, and advancements in medical research and technology. The rising incidence of colorectal cancer, coupled with the development of innovative treatment modalities, contributes significantly to market expansion. Collaborations between pharmaceutical companies and research institutions further fuel growth.

Colorectal Cancer Therapeutics Market Scope

Report Coverage Details
Market Size in 2023 USD 12.23 Billion
Market Size by 2032 USD 18.25 Billion
Growth Rate from 2023 to 2032 CAGR of 4.55%
Largest Market North America
Base Year 2022
Forecast Period 2023 to 2032
Segments Covered By Therapy, By Cancer Type, and By Distribution Channel
Regions Covered North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa


Key drivers in the market include a surge in early cancer detection initiatives, government-supported screening programs, and a growing emphasis on personalized medicine. Advances in genomics and molecular diagnostics contribute to the identification of specific biomarkers, enabling targeted therapies that enhance treatment efficacy while minimizing adverse effects.


Opportunities in the Colorectal Cancer Therapeutics Market lie in the exploration of novel therapeutic avenues, the expansion of market penetration in developing regions, and the integration of digital health technologies for improved patient outcomes. Additionally, the growing focus on precision medicine opens doors for tailored treatment options and personalized therapeutic approaches.


Challenges faced by the market encompass high treatment costs, accessibility issues, and the intricacies of developing effective immunotherapies. Resistance to conventional therapies and the need for comprehensive diagnostic tools pose additional hurdles. Navigating these challenges necessitates collaborative efforts between healthcare providers, researchers, and pharmaceutical companies.

Competition Landscape:

The Colorectal Cancer Therapeutics Market features a competitive landscape marked by key pharmaceutical players engaged in research, development, and commercialization of therapeutic interventions. Notable companies invest in clinical trials, strategic partnerships, and mergers to strengthen their market position. Competition is intensified as companies strive to introduce innovative therapies, gain regulatory approvals, and expand their global reach to meet the evolving demands of colorectal cancer treatment.

Read Also: AI in Life Science Analytics Market Size to Garner USD 5.10 Billion by 2032

Recent Developments

  • November 2023: U.S. FDA (Food and Drug Administration) announced that it has approved Takeda’s oral targeted therapy for adults with metastatic colorectal cancer (mCRC), FRUZAQLA (fruquintinib). According to the company, FRUZAQLA is a chemotherapy-free treatment option and provide a considerable survival help to patients without much impacting their quality of life.
  • August 2023: U.S. Food and Drug Administration (FDA) has approved Taiho Pharmaceutical Co., Ltd. and Taiho Oncology, Inc., LONSURF (trifluridine/tipiracil), to treat adult patients with metastatic colorectal cancer (mCRC) as a single agent or in combination with bevacizumab.
  • June 2023: Enzene Biosciences has launched its cheaper drug for treatment of metastatic colorectal cancer, Bevacizumab. It is a biosimilar substitute to the more expensive Avastin.

Colorectal Cancer Therapeutics Market Players

  • Bayer AG
  • Bristol Myers Squibb
  • Eli Lilly and Company
  • Genentech, Inc.
  • Ipsen Biopharmaceuticals, Inc.
  • Merck Sharp & Dohme Corp.
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • Taiho Pharmaceutical (Otsuka Pharmaceutical Co., Ltd.)
  • Novartis AG

Segments Covered in the Report

By Therapy

  • Targeted Therapy
  • Immunotherapy
  • Chemotherapy
  • Others

By Cancer Type

  • Colorectal Adenocarcinoma
  • Gastrointestinal Carcinoid Tumors
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333







Fabio Thomas 

Fabio Thomas 

Fabio is a Senior Editor at Reports Gazette who focused on healthcare it news. Also, he is a writer and public health researcher.  He joins Reports Gazette from Modern Healthcare, where he worked as a web producer since 2020. Before joining the Modern Healthcare team, Fabio received a master’s degree in journalism from Northwestern University. He is the author of a 2016-17 book, he is also the recipient of numerous awards.

View all posts by Fabio Thomas  →

Leave a Reply

Your email address will not be published. Required fields are marked *